- Home
- UPXI vs CNTB Comparison
UPXI vs CNTB Comparison
Compare UPXI & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPXI | CNTB |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.9M | 128.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UPXI | CNTB |
|---|---|---|
| Price | $1.98 | $2.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 4.1M | 87.3K |
| Earning Date | 02-13-2026 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $20,694,575.00 | $762,000.00 |
| Revenue This Year | $141.57 | N/A |
| Revenue Next Year | $14.83 | $24,739.01 |
| P/E Ratio | $1.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.67 | $0.51 |
| 52 Week High | $22.57 | $3.28 |
Technical Indicators
Market Signals| Indicator | UPXI | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 55.40 |
| Support Level | $1.97 | $2.10 |
| Resistance Level | $2.17 | $2.88 |
| Average True Range (ATR) | 0.22 | 0.23 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 13.93 | 60.44 |
Price Performance
Historical ComparisonAbout UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.